Skip to contentD
DNA X, Inc.
D
SONMDNA X, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.93M$15.93Mderived+0.6% vs Q4 2020 Net Income-$11.72M-$11.72MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DNA X, Inc. · CIK 1178697 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$487,000N/M Operating Incomederived-$11,742,000N/M Operating Cash Flowderived-$17,564,000N/M Free Cash Flowderived-$17,590,000N/M Margins · derivedGross margin-3.1%−26.6 pt vs Q4 2020
Operating margin-73.7%−26.6 pt vs Q4 2020
Net margin-73.6%−33.1 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 21, 2022 · 80 d after period end